News - GW Pharmaceuticals, Pharmaceutical

Filter

Popular Filters

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

US FDA grants Fast Track designation for GW Pharma’s Epidiolex in Dravet syndrome

06-06-2014

The US Food and Drug Administration has granted Fast Track designation to UK-based GW Pharmaceuticals’…

epidiolexGW PharmaceuticalsPharmaceuticalRare diseasesRegulationTreatment of Dravet syndromeUSA

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

GW Pharma and New York State to initiate trials of cannabidiol in epilepsy

04-06-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

epidiolexGW PharmaceuticalsMedication-resistant epilepsyNeurologicalPharmaceuticalResearchUSA

GW Pharma shows drop in revenue but expects ‘steady progress’

GW Pharma shows drop in revenue but expects ‘steady progress’

07-05-2014

UK-based GW Pharmaceuticals, a biopharmaceutical company focused on developing novel therapeutics from…

FinancialGW PharmaceuticalsNeurologicalPharmaceuticalSativexUK

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

GW Pharmaceuticals appoints Kenneth Sommerville as VP, Clinical Science

07-05-2014

UK-based GW Pharmaceuticals has announced the appointment of Kenneth Sommerville to the newly created…

BoardroomGW PharmaceuticalsPharmaceuticalUKUSA

US FDA grants Sativex fast track status for cancer pain

US FDA grants Sativex fast track status for cancer pain

28-04-2014

UK-based GW Pharmaceuticals, which focuses on its proprietary cannabinoid product platform, today announced…

Advanced cancerAnalgesiaCancerGW PharmaceuticalsOncologyOptimized chronic opioid therapyPainPharmaceuticalRegulationSativexTreatment of pain in patients with advanced cancerUK

GW Pharmaceuticals updates on cannabinoid pipeline

GW Pharmaceuticals updates on cannabinoid pipeline

17-03-2014

UK biopharma company GW Pharmaceuticals this morning provided an update on the company’s cannabinoid…

DiabetesepidiolexGW PharmaceuticalsGWP42004GWP42006NeurologicalPharmaceuticalResearchSativex

US orphan status for GW Pharma’s Epidiolex in Lennox-Gastaut syndrome

28-02-2014

UK-based GW Pharmaceuticals says that the Food and Drug Administration has granted orphan drug designation…

epidiolexGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationUSA

GW Pharma revenues rise but 1st-qtr loss incurred

GW Pharma revenues rise but 1st-qtr loss incurred

05-02-2014

Shares of UK-based cannabis-based drug developer GW Pharmaceuticals fell 3,9% to 287.39 pence this morning,…

epidiolexFinancialGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

Ipsen and GW Pharma to promote Sativex in Latin America; Ipsen will ‘go it alone’ for Somatuline

14-01-2014

French drugmaker Ipsen (Euronext: IPN) and UK-based GW Pharmaceuticals (Nasdaq: GWPH) have entered into…

FranceGW PharmaceuticalsIpsenLicensingPharmaceuticalSativexSomatuline

Sativex approved for MS in Switzerland

Sativex approved for MS in Switzerland

27-11-2013

UK-based GW Pharmaceuticals (AIM: GWP), which is focused on novel cannaboid therapeutics, has received…

AlmirallCNS DiseasesEuropeGW PharmaceuticalsPharmaceuticalRegulationSativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

GW Pharma sees fiscal 2012/3 revenues decline, impacted by Sativex

19-11-2013

UK-based GW Pharmaceuticals (AIM: GWP) which is focused on novel cannaboid therapeutics, has announced…

CNS DiseasesFinancialGW PharmaceuticalsPharmaceuticalSativexUK

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

GW Pharma receives FDA orphan drug designation for cannaboid-based agent

15-11-2013

GW Pharmaceuticals (Nasdaq: GWPH) has been granted orphan drug designation by the US Food and Drug Administration…

EuropeGW PharmaceuticalsNorth AmericaPharmaceuticalRare diseasesRegulationUKUSA

Agreement reached for Sativex pricing in Germany

25-09-2013

A German unit of Spain’s largest drugmaker Almirall, Hermal GmbH and Germany’s National Association…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingSativex

GW Pharma goes into 3rd-qtr loss

05-08-2013

UK-based GW Pharmaceuticals (Nasdaq: GWPH, AIM: GWP) which is focused on discovering, developing and…

FinancialGW PharmaceuticalsPharmaceuticalSativex

GW Pharma posts six-month results; progresses cannabinoid pipeline including into diabetes and UC

05-06-2013

UK biopharma company GW Pharmaceuticals (AIM: GWP), which is developing and commercializing novel therapeutics…

DiabetesFinancialGastro-intestinalsGW PharmaceuticalsNeurologicalPharmaceuticalResearchSativex

Almirall pays GW Pharma milestone on Sativex; reports 1st-qtr results

07-05-2013

UK-based GW Pharmaceuticals (AIM: GWP) says that it has received commercialization approval for its cannabinoid-based…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

Bayer's PAH drug candidate riociguat gets US priority review; Sativex rescheduled in UK

08-04-2013

The US Food and Drug Administration has granted priority review to German drug major Bayer's (BAYN: DE)…

BayerEuropeGW PharmaceuticalsNeurologicalNorth AmericaPharmaceuticalRegulationRespiratory and PulmonaryriociguatSativex

Almirall could pull Sativex from German market due to inadequate pricing

20-03-2013

Almirall (ALM: MC), Spain's largest pharma company and the licensee for UK-based GW Pharmaceuticals'…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingSativex

Highlights from ECTRIMS include new data for Gilenya, Sativex and Aubagio

14-10-2012

New data presented at the 28th congress of the European Committee for Treatment and Research in Multiple…

AlmirallAubagioBiotechnologyGenzymeGilenyaGW PharmaceuticalsNeurologicalNovartisPharmaceuticalResearchSanofiSativex

Spanish reforms and generics hit Almirall's 1st-qtr; Sativex progress

09-05-2012

Spain's leading drugmaker Almirall (ALM: MC) has reported a 5.9% decrease in sales for the first quarter…

AlmirallEuropeFinancialGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

No proof of added benefit of Sativex, says German IQWiG

17-04-2012

In an early benefit assessment under to the German Act on the Reform of the Market for Medicinal Products…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalPricingRegulationSativex

GW Pharma and Almirall extend Sativex deal to Mexico

15-03-2012

UK-based GW Pharmaceuticals (AIM: GWP) announces that it has signed an amendment to its cannabis-based…

AlmirallFinancialGW PharmaceuticalsLicensingNeurologicalPharmaceuticalSativexSouth America

GW Pharma’s Sativex cleared in Austria

07-02-2012

The UK’s GW Pharmaceuticals’ (AIM: GWP) Sativex (delta-9-tetrahydrocannabinol (THC) and cannabidiol…

AlmirallEuropeGW PharmaceuticalsNeurologicalPharmaceuticalRegulationSativex

Back to top